Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 5.6% during mid-day trading on Tuesday . The company traded as low as C$0.09 and last traded at C$0.09. Approximately 74,700 shares were traded during trading, an increase of 6% from the average daily volume of 70,178 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Performance
The firm has a market cap of C$7.41 million, a price-to-earnings ratio of -4.25 and a beta of 0.15. The business has a 50 day simple moving average of C$0.06 and a 200-day simple moving average of C$0.05.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Further Reading
- Five stocks we like better than Hemostemix
- The How And Why of Investing in Oil Stocks
- What’s Next After FOMC’s Aggressive Interest Rate Cuts?
- How to Evaluate a Stock Before Buying
- Verizon Stock: 5G Boom and Robust Dividend Yield at Play
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Stocks with Upgraded Ratings: Analysts Predict More Upside
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.